Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8+ T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits

Callie E. Bounds, Jiafen Hu, Nancy M. Cladel, Karla Balogh, Neil D. Christensen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The newly established HLA-A2.1 transgenic rabbit model has proven useful for testing the immunogenicity of well known and computer-predicted A2-restricted epitopes. In the current study we compared the protective immunity induced to a preferred HPV16 E7 A2-restricted epitope that has been relocated to positions within the CRPV E7 gene and the CRPV L2 gene. Epitope expression from both the E7 protein and the L2 protein resulted in increased protection against viral DNA challenge of the HLA-A2.1 transgenic rabbits as compared to control-vaccinated rabbit groups. These data indicate that proteins expressed at both early and late time points during a natural papillomavirus infection can be targeted by epitope-specific immunity and indicate this immunity is increased to early rather than late expressed proteins of papillomaviruses. This study also highlights the broad utility of the HLAA2.1 transgenic rabbit model for testing numerous immunological factors involved in vaccine generated protective immunity.

Original languageEnglish (US)
Pages (from-to)1194-1200
Number of pages7
JournalVaccine
Volume29
Issue number6
DOIs
StatePublished - Feb 1 2011

Fingerprint

Cottontail rabbit papillomavirus
T-Lymphocyte Epitopes
epitopes
Epitopes
Immunity
Vaccines
T-lymphocytes
immunity
rabbits
genetically modified organisms
Genome
vaccines
Rabbits
genome
Papillomaviridae
varespladib methyl
Genes
Proteins
genes
proteins

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

@article{3ed3c665c02e41ceba278e4261aaeb18,
title = "Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8+ T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits",
abstract = "The newly established HLA-A2.1 transgenic rabbit model has proven useful for testing the immunogenicity of well known and computer-predicted A2-restricted epitopes. In the current study we compared the protective immunity induced to a preferred HPV16 E7 A2-restricted epitope that has been relocated to positions within the CRPV E7 gene and the CRPV L2 gene. Epitope expression from both the E7 protein and the L2 protein resulted in increased protection against viral DNA challenge of the HLA-A2.1 transgenic rabbits as compared to control-vaccinated rabbit groups. These data indicate that proteins expressed at both early and late time points during a natural papillomavirus infection can be targeted by epitope-specific immunity and indicate this immunity is increased to early rather than late expressed proteins of papillomaviruses. This study also highlights the broad utility of the HLAA2.1 transgenic rabbit model for testing numerous immunological factors involved in vaccine generated protective immunity.",
author = "Bounds, {Callie E.} and Jiafen Hu and Cladel, {Nancy M.} and Karla Balogh and Christensen, {Neil D.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.vaccine.2010.12.002",
language = "English (US)",
volume = "29",
pages = "1194--1200",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8+ T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits

AU - Bounds, Callie E.

AU - Hu, Jiafen

AU - Cladel, Nancy M.

AU - Balogh, Karla

AU - Christensen, Neil D.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - The newly established HLA-A2.1 transgenic rabbit model has proven useful for testing the immunogenicity of well known and computer-predicted A2-restricted epitopes. In the current study we compared the protective immunity induced to a preferred HPV16 E7 A2-restricted epitope that has been relocated to positions within the CRPV E7 gene and the CRPV L2 gene. Epitope expression from both the E7 protein and the L2 protein resulted in increased protection against viral DNA challenge of the HLA-A2.1 transgenic rabbits as compared to control-vaccinated rabbit groups. These data indicate that proteins expressed at both early and late time points during a natural papillomavirus infection can be targeted by epitope-specific immunity and indicate this immunity is increased to early rather than late expressed proteins of papillomaviruses. This study also highlights the broad utility of the HLAA2.1 transgenic rabbit model for testing numerous immunological factors involved in vaccine generated protective immunity.

AB - The newly established HLA-A2.1 transgenic rabbit model has proven useful for testing the immunogenicity of well known and computer-predicted A2-restricted epitopes. In the current study we compared the protective immunity induced to a preferred HPV16 E7 A2-restricted epitope that has been relocated to positions within the CRPV E7 gene and the CRPV L2 gene. Epitope expression from both the E7 protein and the L2 protein resulted in increased protection against viral DNA challenge of the HLA-A2.1 transgenic rabbits as compared to control-vaccinated rabbit groups. These data indicate that proteins expressed at both early and late time points during a natural papillomavirus infection can be targeted by epitope-specific immunity and indicate this immunity is increased to early rather than late expressed proteins of papillomaviruses. This study also highlights the broad utility of the HLAA2.1 transgenic rabbit model for testing numerous immunological factors involved in vaccine generated protective immunity.

UR - http://www.scopus.com/inward/record.url?scp=78751567929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751567929&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.12.002

DO - 10.1016/j.vaccine.2010.12.002

M3 - Article

C2 - 21167863

AN - SCOPUS:78751567929

VL - 29

SP - 1194

EP - 1200

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 6

ER -